TY - JOUR
T1 - Nosology and classification of genetic skeletal disorders
T2 - 2006 Revision
AU - Superti-Furga, Andrea
AU - Unger, Sheila
AU - Beighton, Peter
AU - Bonafé, Luisa
AU - Braverman, Nancy
AU - Briggs, Michael
AU - Cohn, Dan
AU - Cormier-Dairé, Valerie
AU - Francomano, Clair
AU - Hall, Christine
AU - Horton, William
AU - Kaitila, Ilkka
AU - Krakow, Deborah
AU - Lachman, Ralph
AU - Lee, Brendan
AU - LeMerrer, Martine
AU - Mortier, Geert
AU - Mundlos, Stephan
AU - Nishimura, Gen
AU - Poznanski, Andrew
AU - Rimoin, David
AU - Robertson, Stephen
AU - Savarirayan, Ravi
AU - Spranger, Jurgen
AU - Sillence, David
AU - Warman, Matthew
AU - Wilcox, William
AU - Wilkie, Andrew
AU - Zabel, Bernhard
AU - Zankl, Andreas
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The objective of the paper is to provide the revision of the Nosology of Constitutional Disorders of Bone that incorporates newly recognized disorders and reflects new molecular and pathogenetic concepts. Criteria for inclusion of disorders were (1) significant skeletal involvement corresponding to the definition of skeletal dysplasias, metabolic bone disorders, dysostoses, and skeletal malformation and/or reduction syndromes, (2) publication and/or MIM listing, (3) genetic basis proven or very likely, and (4) nosologic autonomy confirmed by molecular or linkage analysis and/or distinctive diagnostic features and observation in multiple individuals or families. Three hundred seventy-two different conditions were included and placed in 37 groups defined by molecular, biochemical and/or radiographic criteria. Of these conditions, 215 were associated with one or more of 140 different genes. Nosologic status was classified as final (mutations or locus identified), probable (pedigree evidence), or bona fide (multiple observations and clear diagnostic criteria, but no pedigree or locus evidence yet). The number of recognized genetic disorders with a significant skeletal component is growing and the distinction between dysplasias, metabolic bone disorders, dysostoses, and malformation syndromes is blurring. For classification purposes, pathogenetic and molecular criteria are integrating with morphological ones but disorders are still identified by clinical features and radiographic appearance. Molecular evidence leads to confirmation of individual entities and to the constitution of new groups, but also allows for delineation of related but distinct entities and indicates a previously unexpected heterogeneity of molecular mechanisms; thus, molecular evidence does not necessarily simplify the Nosology, and a further increase in the number of entities and growing complexity is expected. By providing an updated overview of recognized entities with skeletal involvement and of the underlying gene defects, the new Nosology can provide practical diagnostic help, facilitate the recognition of new entities, and foster and direct research in skeletal biology and genetic disorders.
AB - The objective of the paper is to provide the revision of the Nosology of Constitutional Disorders of Bone that incorporates newly recognized disorders and reflects new molecular and pathogenetic concepts. Criteria for inclusion of disorders were (1) significant skeletal involvement corresponding to the definition of skeletal dysplasias, metabolic bone disorders, dysostoses, and skeletal malformation and/or reduction syndromes, (2) publication and/or MIM listing, (3) genetic basis proven or very likely, and (4) nosologic autonomy confirmed by molecular or linkage analysis and/or distinctive diagnostic features and observation in multiple individuals or families. Three hundred seventy-two different conditions were included and placed in 37 groups defined by molecular, biochemical and/or radiographic criteria. Of these conditions, 215 were associated with one or more of 140 different genes. Nosologic status was classified as final (mutations or locus identified), probable (pedigree evidence), or bona fide (multiple observations and clear diagnostic criteria, but no pedigree or locus evidence yet). The number of recognized genetic disorders with a significant skeletal component is growing and the distinction between dysplasias, metabolic bone disorders, dysostoses, and malformation syndromes is blurring. For classification purposes, pathogenetic and molecular criteria are integrating with morphological ones but disorders are still identified by clinical features and radiographic appearance. Molecular evidence leads to confirmation of individual entities and to the constitution of new groups, but also allows for delineation of related but distinct entities and indicates a previously unexpected heterogeneity of molecular mechanisms; thus, molecular evidence does not necessarily simplify the Nosology, and a further increase in the number of entities and growing complexity is expected. By providing an updated overview of recognized entities with skeletal involvement and of the underlying gene defects, the new Nosology can provide practical diagnostic help, facilitate the recognition of new entities, and foster and direct research in skeletal biology and genetic disorders.
KW - Developmental biology
KW - Dysostoses
KW - Malformation syndromes
KW - Molecular defects
KW - Nosology
KW - Osteochondrodysplasias
KW - Skeletal disorders
UR - http://www.scopus.com/inward/record.url?scp=33845971924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845971924&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.31483
DO - 10.1002/ajmg.a.31483
M3 - Review article
C2 - 17120245
AN - SCOPUS:33845971924
SN - 1552-4825
VL - 143
SP - 1
EP - 18
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 1
ER -